Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep clinical development and product approval exp ...

Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercializationAndrew Miller ...

The U.S. Food and Drug Administration approved Cobenfy on September 26, 2024, making it the first schizophrenia drug with a fundamentally new mechanism of action in more than half a century. Built on ...

Bristol-Myers' total return more than doubled S&P 500 performance since I opened my Long position. Fast-forward to 2026, all eyes should be on the upcoming $30B patent cliff as the Growth portfolio ...

For months now, all signs have pointed to a looming, steep dropoff in pharmas’ spending on traditional TV advertising. One brand that seems not to have gotten the memo, however, is Johnson & Johnson’s ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best long-term stocks to invest in for retirement. On February 10, Bernstein SocGen Group reiterated its Market Perform rating and $58 price ...

ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...

This stock has been known to soar after good news. When most people think about GLP-1 drugs, they think of the blockbuster products sold by pharma giants Eli Lilly and Novo Nordisk. Lilly makes ...

India, Feb. 11 -- Karuna Gopal, President Foundation for Futuristic Cities and Board Director , Engineers India Ltd under Petroleum Ministry has been conferred with an International award "Nelson ...

In a head-to-head preclinical comparison, HT-VA co-developed with the United States Veterans Administration GDNF demonstrated superior efficacy compared with semaglutide (the active ingredient in ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...